iRhythm Technologies, Inc. reported significant financial performance improvements in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated $192.9 million in net revenue for the third quarter, a 31% increase from $147.5 million in the same period last year. For the nine months ended September 30, 2025, revenue reached $538.2 million, up 26% from $427.5 million in the prior year. The growth was primarily driven by increased demand for iRhythm Services, particularly from larger healthcare enterprise accounts utilizing both the Zio Monitor and Zio AT products.
Despite the revenue growth, iRhythm reported a net loss of $5.2 million for the third quarter, a notable improvement from a loss of $46.2 million in the same quarter of 2024. The nine-month net loss also decreased to $50.1 million from $112.0 million year-over-year. The company attributed the reduced losses to higher revenue volumes and improved operational efficiencies, although it faced challenges such as increased contractual allowance reserves and higher claims denials.
Operationally, iRhythm has expanded its customer base, with significant growth in the adoption of its Zio AT product. The company has provided its services to over eight million patients, accumulating more than two billion hours of curated heartbeat data. The total employee headcount has also increased, reflecting the company's ongoing investment in its workforce to support growth and innovation. Additionally, iRhythm has continued to enhance its technology, including the development of new product offerings and improvements to existing services.
Strategically, iRhythm entered into a Technology License Agreement with BioIntelliSense, Inc. in August 2024, which allows the company to develop and commercialize new technologies for its ambulatory cardiac monitoring products. The agreement included an upfront payment of $15 million and the purchase of convertible promissory notes. The company also reported a decrease in acquired in-process research and development expenses, reflecting a shift in focus towards more sustainable product development initiatives.
Looking ahead, iRhythm remains optimistic about its growth trajectory, despite macroeconomic challenges such as inflation and supply chain disruptions. The company believes its current cash and marketable securities, totaling approximately $565.2 million, will be sufficient to meet its liquidity needs for at least the next 12 months. iRhythm is committed to enhancing its operational capabilities and expanding its market presence, with plans to continue investing in research and development to drive future growth.
About iRhythm Technologies, Inc.
iRhythm Technologies Inc. specializes in digital healthcare solutions for cardiac arrhythmia detection through device-based ambulatory monitoring. Its core products include the Zio System, a wire-free, patch-based ECG monitor, and related services that enable long-term, high-accuracy heart rhythm analysis. Serving healthcare providers globally, the company leverages proprietary AI, clinical data, and regulatory expertise to improve diagnosis, reduce costs, and support proactive patient management.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.